Mosunetuzumab Biosimilar – Research Grade
ichorbio’s mosunetuzumab biosimilar is for Research Use Only (RUO) and not for therapeutic use.
ichorbio’s RUO mosunetuzumab biosimilar is available in the following sizes:
0.1mg, 5mg, 10mg, 20mg, 50mg
ichorbio regularly manufactures bulk multi-gram amounts of this biosimilar – please contact us for pricing.
Detects human CD3/CD20. This non-therapeutic antibody uses the same sequence as mosunetuzumab.
This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
ichorbio’s Mosunetuzumab biosimilar is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells..
1.0 – 5.0 mg/ml
Sterile, preservative-free, solution in PBS. BSA and Azide free.
>95% by SDS-PAGE and HPLC
≤ 1.0 EU/mg as determined by the LAL method
Mosunetuzumab biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Each investigator should determine their own optimal working dilution for specific applications.
ichorbio’s mosunetuzumab biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.